今晚7点,互动有奖!~全文共919字预计阅读时间:5分钟2025年7月17日,专注于精准免疫肿瘤药物研发的全球性生物技术公司I-Mab宣布达成最终协议,收购Bridge Health Biotech Co., Ltd.(Bridge Health)100%股权。此次交易将为I-Mab带来其CLDN18.2×4-1BB双特异性抗体Givastomig所使用的CLDN18.2亲本抗体在双特异性及多...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.